L-Leucyl-L-Leucine methyl ester (hydrobromide)

L-Leucyl-L-Leucine methyl ester (LLOMe) hydrobromide, a dipeptide condensation product of L-leucine methyl ester generated by human monocytes or polymorphonuclear leukocytes, selectively eliminates lymphocytes with cytotoxic potential. L-Leucyl-L-Leucine methyl ester hydrobromide also can induce endolysosomal pathway stress[1][2][3].

Product Specifications

CAS Number

[16689-14-8]

Product Name Alternative

LLOMe (hydrobromide) ; Leu-Leu methyl ester (hydrobromide) ; H-Leu-Leu-OMe (hydrobromide)

UNSPSC

12352211

Target

Endogenous Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/l-leucyl-l-leucine-methyl-ester-hydrobromide.html

Purity

99.69

Solubility

DMSO : 125 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

CC(C)C[C@@H](C(OC)=O)NC([C@H](CC(C)C)N)=O.[H]Br

Molecular Formula

C13H27BrN2O3

Molecular Weight

339.27

References & Citations

[1]Thiele DL, et, al. The immunosuppressive activity of L-leucyl-L-leucine methyl ester: selective ablation of cytotoxic lymphocytes and monocytes. J Immunol. 1986 Feb 1;136 (3) :1038-48.|[2]Thiele DL, et, al. Mechanism of L-leucyl-L-leucine methyl ester-mediated killing of cytotoxic lymphocytes: dependence on a lysosomal thiol protease, dipeptidyl peptidase I, that is enriched in these cells. Proc Natl Acad Sci U S A. 1990 Jan;87 (1) :83-7.|[3]Kalogeropulou AF, et, al. Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity. Biochem J. 2020 Nov 27;477 (22) :4397-4423.